These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28398109)

  • 41. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
    Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A large, benign prostatic cyst presented with an extremely high serum prostate-specific antigen level.
    Chen HK; Pemberton R
    BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26746834
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml.
    Wang X; Wang JY; Li CM; Zhang YQ; Wang JL; Wan B; Zhang W; Chen M; Li SY; Wan G; Liu M
    Chin Med J (Engl); 2016 Jun; 129(12):1432-8. PubMed ID: 27270538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
    Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
    Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Diagnosis of prostate capsular invasion by pelvic magnetic resonance imaging and serum level of prostate specific antigen].
    Mikata K; Uemura H; Fujinami K; Ohuchi H; Miyoshi Y; Ohta J; Osada Y; Jinza S; Kubota Y; Hosaka M; Nakatani I; Takebayashi S
    Hinyokika Kiyo; 2001 Jun; 47(6):385-8. PubMed ID: 11496393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis.
    Filella X; Giménez N
    Clin Chem Lab Med; 2013 Apr; 51(4):729-39. PubMed ID: 23154423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
    Lamy PJ; Montels F; Tosi D; Leizour B; Bascoul-Mollevi C; Castan F; Roques S; Nielloud F; Rebillard X
    Ann Biol Clin (Paris); 2013; 71(5):537-44. PubMed ID: 24113439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pro-prostate-specific antigen and its related indexes in the diagnosis of prostate cancer].
    Jiang L; Lu YP
    Zhonghua Nan Ke Xue; 2015 Jul; 21(7):655-8. PubMed ID: 26333230
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Current role of protatic specific antigen (PSA) and its by-products in the diagnosis of prostate cancer].
    Placer J; Planas J; Celma A; Morote J
    Arch Esp Urol; 2015 Apr; 68(3):210-28. PubMed ID: 25948795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.
    Malik G; Ward MD; Gupta SK; Trosset MW; Grizzle WE; Adam BL; Diaz JI; Semmes OJ
    Clin Cancer Res; 2005 Feb; 11(3):1073-85. PubMed ID: 15709174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
    Moul JW; Tang P; Sun L
    Eur Urol; 2010 Mar; 57(3):452. PubMed ID: 19303696
    [No Abstract]   [Full Text] [Related]  

  • 54. Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms.
    Kitata RB; Hu LY; Lin TT; Nicora CD; Fillmore TL; Nie S; Hudson RD; Liu T; Leach RJ; Liu AY; Qian WJ; Shi T
    J Proteome Res; 2023 Mar; 22(3):942-950. PubMed ID: 36626706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer.
    Price CP; Allard J; Davies G; Dawnay A; Duffy MJ; France M; Mandarino G; Ward AM; Patel B; Sibley P; Sturgeon C
    Ann Clin Biochem; 2001 May; 38(Pt 3):188-216. PubMed ID: 11392495
    [No Abstract]   [Full Text] [Related]  

  • 56. Re: The Value of Magnetic Resonance Imaging in the Detection of Prostate Cancer in Patients with Previous Negative Biopsies and Elevated Prostate-Specific Antigen Levels: A Meta-Analysis.
    Siegel C
    J Urol; 2015 Aug; 194(2):395. PubMed ID: 26195367
    [No Abstract]   [Full Text] [Related]  

  • 57. Prostate specific antigen: an updated review.
    So A; Goldenberg L; Gleave ME
    Can J Urol; 2003 Dec; 10(6):2040-50. PubMed ID: 14704108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Editorial Comment from Dr Satoh to interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer.
    Satoh T
    Int J Urol; 2013 Feb; 20(2):149. PubMed ID: 22924812
    [No Abstract]   [Full Text] [Related]  

  • 59. Editorial Comment from Dr Stone to interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer.
    Stone NN
    Int J Urol; 2013 Feb; 20(2):148. PubMed ID: 22924786
    [No Abstract]   [Full Text] [Related]  

  • 60. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.
    Bangma CH; Wildhagen MF; Yurdakul G; Schröder FH; Blijenberg BG
    BJU Int; 2004 Apr; 93(6):720-4. PubMed ID: 15049979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.